Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8044344 | 0.89 | MAPK14 (0.58) | MAPK14RIPK2BTKSCN9A | |
| SCHEMBL3376470 | 0.88 | MAPK14 (0.77) | MAPK14RIPK2PTPN1SCN9A | |
| SCHEMBL18172047 | 0.86 | MAPK14 (0.59) | MAPK14RIPK2PTPN1BTKSCN9A | |
| SCHEMBL14692631 | 0.86 | MAPK14 (0.52) | MAPK14RIPK2PTPN1SCN9A | |
| SCHEMBL3373162 | 0.84 | MAPK14 (0.55) | MAPK14RIPK2PTPN1 | |
| SCHEMBL3373304 | 0.77 | PTPN1 (0.55) | MAPK14RIPK2PTPN1SCN9A | |
| SCHEMBL14692428 | 0.77 | FGFR1 (0.51) | MAPK14RIPK2PTPN1SCN9A | |
| SCHEMBL3376472 | 0.77 | MAPK14 (0.58) | MAPK14RIPK2PTPN1SCN9A | |
| SCHEMBL1691549 | 0.77 | MAPK14 (0.72) | MAPK14RIPK2SCN9A | |
| SCHEMBL3374482 | 0.77 | FGFR1 (0.62) | MAPK14RIPK2PTPN1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501003-B | Phenyl-pyrazole derivatives as non-steroidal glucocorticoid receptor ligands | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| EP-2029549-B1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-2099766-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | Glaxo Group Limited (GB) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008074814-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | MAPK14 1393/4885RIPK2 1523/4885PTPN1 3482/4885 |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, CYP11B2 | MAPK14 602/4885RIPK2 711/4885PTPN1 593/4885 |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | NR3C1, SERPINA6, PTGS1 | MAPK14 530/4885RIPK2 1695/4885PTPN1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.